First Site activated for Enrollment


On April 10th, the Pyhrn-Eisenwurzen Clinic Steyr (2nd Medical Department) under the lead of Principal Investigator Dr. Dieter Rossmann was activated as the first site of the ABCSG 62 / CAMBRIA-2 trial in Austria.

The phase III, open-label, randomised study is assessing the efficacy and safety of Camizestrant (a next generation, oral selective estrogen receptor degrader) versus standard endocrine therapy (aromatase inhibitor or Tamoxifen) as adjuvant treatment. The target population of interest in this study consists of patients with ER+/HER2- early breast cancer with intermediate-high or high risk of recurrence, who have completed definitive locoregional therapy and have no evidence of disease.

The ABCSG 62 / CAMBRIA-2 trial is expected to enroll 5.500 patients worldwide, including 144 patients at 16 sites in Austria. The coordinating investigator for Austria is OA Dr. Daniel Egle from the University Clinic for Gynecology, Innsbruck.

We hope to have our First Patient In (FPI) soon!

You can find more information on the study → here.


More posts on the topic:

Share on